Core--IMMUNOGENETICS OF HUMAN DIABETES

核心--人类糖尿病的免疫遗传学

• 批准号: 7468456
• 负责人: LEROY E HOOD
• 金额: $ 10.15万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7468456
• 关键词: Academic Medical Centers; African; Arts; Childhood; Chromosome Mapping; Core Facility; DNA Sequence; Diabetes Mellitus; France; Genetic; HLA-DQ Antigens; HLA-DR Antigens; Home environment; Institutes; Insulin-Dependent Diabetes Mellitus; Laboratories; Monoclonal Antibodies; Proteins; Proteomics; Research; Research Personnel; Resolution; SNP genotyping; Scientist; Services; Universities; Visit; high throughput technology; human leukocyte antigen gene; medical schools; programs

The objective of the Core B facility is to provide expertise and a state of the art facility for large scale, high-resolution genetic mapping, DNA sequencing and state of the art proteomics. The core facility will provide HLA-DQ and HLA-DR typing for all the projects in the program and will perform high throughput SNP genotyping on type 1 diabetes candidate loci other than HLA genes (project 4). Suggestive results will be typed in other projects for confirmation. We will also provide sequencing services for the characterization of GAD65 monoclonal antibodies (project 2) and proteomics analysis for the identification of antigenic proteins in type 1 and type 1.5 diabetes (project 3). These high throughput technologies will aid the program project investigators to determine the genetic, environmental and immunological features which can help predict and cure type 1 diabetes.

核心B设施的目标是为大规模、高分辨率遗传图谱、DNA测序和最先进的蛋白质组学提供专业知识和最先进的设施。核心设施将为项目中的所有项目提供HLA-DQ和HLA-DR分型，并将对HLA基因以外的1型糖尿病候选位点进行高通量SNP基因分型（项目4）。建议性结果将在其他项目中输入以供确认。我们还将提供GAD 65单克隆抗体表征的测序服务（项目2）和蛋白质组学分析，用于鉴定1型和1.5型糖尿病的抗原蛋白（项目3）。这些高通量技术将帮助项目研究人员确定有助于预测和治愈1型糖尿病的遗传、环境和免疫学特征。